1. Signaling Pathways
  2. MAPK/ERK Pathway
  3. JNK

JNK

JNKs (c-Jun N-terminal kinases) belong to the mitogen-activated protein kinase family, and are responsive to stress stimuli, such as cytokines,ultraviolet irradiation, heat shock, and osmotic shock. JNKs play a role in T cell differentiation and the cellular apoptosis pathway. Activation occurs through a dual phosphorylation of threonine (Thr) and tyrosine (Tyr) residues within a Thr-Pro-Tyr motif located in kinase subdomain VIII. Activation is carried out by two MAP kinases, MKK4 and MKK7 and JNK can be inactivated by Ser/Thr and Tyr protein phosphatases. Downstream molecules that are activated by JNK include c-Jun, ATF2, ELK1, SMAD4, p53 and HSF1. JNKs can associate with scaffold proteins JNK interacting proteins as well as their upstream kinases JNKK1 and JNKK2 following their activation. JNK activity regulates several important cellular functions including cell growth, differentiation, survival and apoptosis.

JNK Isoform Specific Products:

  • JNK1

  • JNK2

  • JNK3

  • JNK

JNK Related Products (31):

Cat. No. Product Name Effect Purity
  • HY-12041
    SP600125 Inhibitor 98.82%
    SP600125 is a cell-permeable, reversible, and ATP-competitive JNK inhibitor with IC50s of 40, 40 and 90 nM for JNK1, JNK2 and JNK3, respectively.
  • HY-18982
    Anisomycin Activator 98.20%
    Anisomycin is a potent protein synthesis inhibitor which interferes with protein and DNA synthesis by inhibiting peptidyl transferase or the 80S ribosome system. Anisomycin is a JNK activator, which increases phospho-JNK.
  • HY-13319
    JNK-IN-8 Inhibitor 99.38%
    JNK-IN-8 is a potent JNK inhibitor with IC50s of 4.7 nM, 18.7 nM, and 1 nM for JNK1, JNK2, and JNK3, respectively.
  • HY-N2149
    Tomatidine Inhibitor >98.0%
    Tomatidine acts as an anti-inflammatory agent by blocking NF-κB and JNK signaling.
  • HY-N0431
    Astragaloside IV Inhibitor 99.15%
    Astragaloside IV, an active component isolated from Astragalus membranaceus, suppresses the activation of ERK1/2 and JNK, and downregulates matrix metalloproteases (MMP)-2, (MMP)-9 in MDA-MB-231 breast cancer cells.
  • HY-107598
    JNK Inhibitor VIII Inhibitor >99.0%
    JNK Inhibitor VIII (TCS JNK 6o) is a c-Jun N-terminal kinases (JNK-1, -2, and -3) inhibitor with Ki values of 2 nM, 4 nM, 52 nM, respectively, and has IC50 values of 45 nM and 160 nM for JNK-1 and -2, respectively.
  • HY-125838
    J30-8 Inhibitor
    J30-8 is a potent and isoform-selective inhibitor of c-Jun N-terminal kinase 3 (JNK3) with an IC50 of 40 nM, which 2500-fold isoform selectivity against JNK1α1 and JNK2α2. J30-8 exhibits neuroprotective activity in vitro and potential for the treatment of neurodegenerative diseases.
  • HY-101287
    MPT0B392 Activator
    MPT0B392, an orally active quinoline derivative, induces c-Jun N-terminal kinase (JNK) activation, leading to apoptosis. MPT0B392 inhibits tubulin polymerization and triggers induction of the mitotic arrest, followed by mitochondrial membrane potential loss and caspases cleavage by activation of JNK and ultimately leads to apoptosis. MPT0B392 is demonstrated to be a novel microtubule-depolymerizing agent and enhances the cytotoxicity of sirolimus in sirolimus-resistant acute leukemic cells and the multidrug resistant cell line.
  • HY-15495
    Tanzisertib Inhibitor 99.92%
    Tanzisertib (CC-930) is a potent JNK1/2/3 inhibitor with IC50s of 61/7/6 nM, respectively.
  • HY-18204A
    LCZ696 Inhibitor 99.99%
    LCZ696 (Sacubitril mixture with Valsartan) is the first angiotensin receptor-neprilysin inhibitor (ARNi) to be used clinically. LCZ696 inhibits the nuclear transfer of NF-κB, JNK/p38MAPK phosphorylation, mitigates inflammation and apoptosis in diabetic mice and H9C2 cardiomyocytes under high-glucose (HG) conditions. LCZ696 is a combination of valsartan and AHU377, at a ratio of 1:1, which is synthesized through a complex chemical reaction, and it attenuats cardiac remodeling and dysfunction after myocardial infarction (MI) by reducing cardiac fibrosis and hypertrophy.
  • HY-P0069
    D-JNKI-1
    D-JNKI-1 is a highly potent and cell-permeable peptide inhibitor of JNK.
  • HY-11010
    AS601245 Inhibitor 98.32%
    AS601245 is a cell-permeable JNK Inhibitor with IC50s of 150, 220, and 70 nM for three JNK human isoforms (hJNK1, hJNK2, and hJNK3), respectively.
  • HY-15617
    JNK-IN-7 Inhibitor 98.05%
    JNK-IN-7 is a potent JNK inhibitor with IC50 of 1.5, 2 and 0.7 nM for JNK1, JNK2 and JNK3, respectively.
  • HY-13022
    CC-401 hydrochloride Inhibitor 99.96%
    CC-401 hydrochloride is a potent inhibitor of all three forms of JNK with Ki of 25 to 50 nM.
  • HY-15737
    DB07268 Inhibitor 99.49%
    DB07268 is a potent and selective JNK1 inhibitor with an IC50 value of 9 nM.
  • HY-10366
    BI-78D3 Inhibitor 99.64%
    BI-78D3 functions as a substrate competitive inhibitor of JNK, inhibit the JNK kinase activity (IC50=280 nM).
  • HY-14761
    Bentamapimod Inhibitor 98.60%
    Bentamapimod (AS 602801) is an ATP-competitive JNK inhibitor with IC50 of 80 nM, 90 nM, and 230 nM for JNK1, JNK2, and JNK3, respectively.
  • HY-N0773
    Isovitexin Inhibitor 98.94%
    Isovitexin is a flavonoid isolated from rice hulls of Oryza sativa, possesses anti-inflammatory and anti-oxidant activities; Isovitexin acts like a JNK1/2 inhibitor and inhibits the activation of NF-κB.
  • HY-15881
    TCS JNK 5a Inhibitor 98.91%
    TCS JNK 5a is a potent JNK3 inhibitor with a pIC50 of 6.7. TCS JNK 5a also inhibits JNK2 with a pIC50 of 6.5.
  • HY-12829
    SR-3306 Inhibitor 99.00%
    SR-3306 is a selective, potent, highly brain penetrant JNK inhibitor.
Isoform Specific Products

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.